

For Immediate Release**TSX Exchange Symbol: RVX****Resverlogix Corp. Granted Foreign Private Issuer Status**

CALGARY, AB, August 23, 2006 – Resverlogix Corp. (“Resverlogix”) (TSX: RVX), has applied for and been granted Foreign Private Issuer status by the US Securities Exchange Commission. Resverlogix Corp. has been advised that it has been added to the list of Foreign Private Issuers that claim exemption pursuant to Rule 12g3-2(b) under the United State Securities Exchange Act of 1934. In order to maintain this exemption, the issuer must furnish the Commission, on a timely basis, all information required by Rule 12g3-2(b).

About Resverlogix Corp.

Resverlogix Corp. is an emerging international biotechnology company that is driven to lead development of novel therapies for important global medical markets with significant unmet medical need. The Company's primary focus is to become a global leader in the research, development and commercialization of novel therapeutics that address the risk of CVD. Through its research efforts the Company has expanded its CVD research to three programs, each addressing different targets for specific commercial markets. NexVas™ Plaque Reduction (PR) is the Company's primary program that targets ApoA-I enhancement via novel small molecules for plaque stabilization and regression. NexVas™ Vascular Inflammation (NexVas VI), the Company's second CVD program, is a research stage technology focused on molecular targets of vascular inflammation. ReVas™ is the Company's third CVD program is dedicated to the research and development of therapeutic compounds to be used with medical devices and biomaterials for the local non-systemic treatment of CVD, in particular restenosis. The Company has partnered this program with world leading medical technology company Medtronic. The Company's second research focused program is TGF–Beta Shield™, a dual focused program that aims to address the unmet medical need of grievous proliferative disease, such as cancer and fibrosis. Resverlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the TSX Exchange under the symbol RVX. For further information, please visit our web site at: www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Kenneth Lebioda
Senior Vice President
Business & Market Development
Resverlogix Corp.
Phone: 403-254-9252
Fax: 403-256-8495
Email: ken@resverlogix.com

Theresa Kennedy
Vice President
Corporate Communications
Resverlogix Corp.
Phone: 403-254-9252
Fax: 403-256-8495
Email: theresa@resverlogix.com

Website: www.resverlogix.com